Table 1. Patient characteristics for all relapsed patients, and those that received reinduction.
| Overall | Reinduced | |
|---|---|---|
| N | 97 | 70 |
| NPM1+ (%) | 39 (40) | 28 (40) |
| Sex (%) | ||
| Female | 43 (44) | 32 (46) |
| Male | 54 (56) | 38 (54) |
| Age at relapse, median (range) | 55 (31–76) | 52 (31–72) |
| <60 (%) | 63 (65) | 54 (77) |
| ⩾60 (%) | 34 (35) | 16 (23) |
| WBC × 109/l, median (range) | 32 (1–207) | 30 (1–207) |
| Prior disease (%) | ||
| De novo | 85 (88) | 63 (90) |
| Secondary | 12 (12) | 7 (10) |
| Cytogenetics | ||
| Diploid | 89 | 64 |
| Abn Y | 3 | 3 |
| +8 | 3 | 2 |
| Other | 2 | 1 |
| Mutation status (%) | ||
| FLT3-/NPM1+ | 20 (21) | 10 (14) |
| FLT3-/NPM1- | 43 (44) | 31 (44) |
| FLT3+ | 34 (31) | 29 (41) |
| CR1 duration (months) | ||
| <6 | 31 (32) | 20 (29) |
| 6–12 | 37 (38) | 25 (36) |
| ⩾12 | 29 (30) | 25 (36) |
| AlloSCT | ||
| None | 74 (76) | 53 (76) |
| Prior alloSCT in CR1 | 4 (4) | 0 (0) |
| AlloSCT in CR2 | 18 (19) | 17 (24) |
Abbreviations: alloSCT, allogeneic stem cell transplant; CR, complete remission; FLT3, fms-like tyrosine kinase-3; NPM1, nucleophosmin-1; WBC, white blood cell.